Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Contaminant Identification and Root Cause Analysis – V 2.0

Posted on By


Biosimilars: SOP for Contaminant Identification and Root Cause Analysis – V 2.0


Standard Operating Procedure for Contaminant Identification and Root Cause Analysis in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/148/2025
Supersedes SOP/BS/148/2022
Page No. Page 1 of 10
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a structured approach for identifying contamination events and performing root cause analysis (RCA) in biosimilar manufacturing, ensuring implementation of corrective and preventive actions (CAPA) and maintaining GMP compliance.

2. Scope

This SOP applies to all microbial, particulate, or chemical contamination events detected during upstream or downstream processes in GMP production, QC labs, and cleanrooms of biosimilar manufacturing facilities.

3. Responsibilities

  • Production: Immediately report suspected contamination and isolate affected area/product.
  • QC Microbiology: Identify, culture, and classify the contaminant.
  • QA: Lead RCA process, approve CAPA, and ensure documentation and closure.

4. Accountability

The Quality Assurance Head is accountable for ensuring all contamination events are investigated, root causes identified, and CAPA executed and tracked to completion.

5. Procedure

5.1 Contamination Detection

  1. Contamination may be detected via:
    • In-process testing (e.g., turbidity, pH shift, unexpected microbial growth)
    • Environmental monitoring (EM)
    • Sterility testing or culture failures
  2. Immediately document findings in Annexure-1: Contamination Incident Report.

5.2 Immediate Actions

  1. Isolate affected equipment, batch, or area.
  2. Stop operations and prevent further contamination spread.
  3. Inform QA and QC within 1 hour.

5.3 Contaminant Identification

  1. QC to collect swab samples, air plates, fluid samples, etc.
  2. Use standard microbiological techniques:
    • Gram staining
    • Colony morphology
    • Biochemical or PCR-based identification (Annexure-2)
  3. If chemical contamination suspected, use FTIR, HPLC, or MS analysis.

5.4 Root Cause Analysis (RCA)

  1. QA to initiate structured RCA within 24 hours using:
    • 5 Whys Technique
    • Fishbone (Ishikawa) diagram
    • FMEA if required
  2. Document findings in Annexure-3: RCA Worksheet.

5.5 Corrective and Preventive Actions (CAPA)

  1. Based on root cause, define:
    • Immediate corrective actions
    • System-level preventive actions (e.g., training, SOP revision, design change)
  2. Track in Annexure-4: CAPA Log and assign completion timeline and responsible personnel.

5.6 Reporting and Closure

  1. Submit final investigation summary to QA Head.
  2. Close the incident in the deviation management system within 30 working days.

6. Abbreviations

  • RCA: Root Cause Analysis
  • CAPA: Corrective and Preventive Action
  • QC: Quality Control
  • EM: Environmental Monitoring
  • FTIR: Fourier-transform infrared spectroscopy

7. Documents

  1. Contamination Incident Report – Annexure-1
  2. Microbial/Chemical Identification Report – Annexure-2
  3. Root Cause Analysis Worksheet – Annexure-3
  4. CAPA Log – Annexure-4

8. References

  • ICH Q9 – Quality Risk Management
  • FDA Guidance on Sterile Manufacturing
  • WHO TRS 986 – GMP for Biologics

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Contamination Incident Report

Date Location Batch No. Description Detected By
03/05/2025 Bioreactor-3 BS-UB-072 Turbidity + pH drop Ajay Verma

Annexure-2: Microbial/Chemical Identification Report

Sample ID Type Method Result Analyst
SMP-BIO-072 Microbial Gram Stain + PCR Bacillus subtilis Sunita Reddy

Annexure-3: RCA Worksheet

Tool Used Root Cause Supporting Evidence Investigator
Fishbone Valve not sterilized post-maintenance Cleaning log missing QA Analyst

Annexure-4: CAPA Log

CAPA ID Action Assigned To Due Date Status
CAPA/BS/073 Revise valve cleaning SOP and retrain Production Head 10/05/2025 Open

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Incorporated chemical contamination assessment and PCR methods Scope Expansion
See also  Biosimilars: SOP for Removal of Host Cell Proteins - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Selection of Excipients for Injectable Products – V 2.0
Next Post: Why Assessing SOP Training Effectiveness Is Crucial in GMP Compliance

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version